Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Bone ; 97: 20-28, 2017 04.
Article in English | MEDLINE | ID: mdl-27939957

ABSTRACT

Sclerostin antibodies increase bone mass by stimulating bone formation. However, human and animal studies show that bone formation increases transiently and returns to pre-treatment level despite ongoing antibody treatment. To understand its mechanism of action, we studied the time course of bone formation, correlating the rate and extent of accrual of bone mass and strength after sclerostin antibody treatment. Ovariectomized (OVX) rats were treated with a sclerostin-antibody (Scle-ab) at 20mg/kg sc once weekly and sacrificed at baseline and 2, 3, 4, 6, and 8weeks post-treatment. In Scle-ab treated rats, serum PINP and OCN rapidly increased at week 1, peaked around week 3, and returned to OVX control levels by week 6. Transcript analyses from the distal femur revealed an early increase in bone formation followed by a sustained decrease in bone resorption genes. Lumbar vertebral (LV) osteoblast surface increased 88% by week 2, and bone formation rate (BFR/BS) increased 138% by week 4. Both parameters were below OVX control by week 8. Bone formation was primarily a result of modeling based formation. Endocortical and periosteal BFR/BS peaked around week 4 at 313% and 585% of OVX control, respectively. BFR/BS then declined but remained higher than OVX control on both surfaces through week 8. Histomorphometric analyses showed LV-BV/TV did not further increase after week 4, while BMD continued to increase at LV, mid femur (MF), and femoral neck (FN) through week 8. Biomechanical tests showed a similar improvement in bone strength through 8weeks in MF and FN, but bone strength plateaued between weeks 6 and 8 for LV. Our data suggest that bone formation with Scle-ab treatment is rapid and modeling formation dominated in OVX rats. Although transient, the bone formation response persists longer in cortical than trabecular bone.


Subject(s)
Antibodies/pharmacology , Bone Morphogenetic Proteins/immunology , Bone and Bones/pathology , Bone and Bones/physiopathology , Genetic Markers/immunology , Osteogenesis/drug effects , Ovariectomy , Animals , Biomarkers/blood , Biomechanical Phenomena , Bone Resorption/blood , Bone Resorption/pathology , Bone and Bones/drug effects , Cancellous Bone/drug effects , Cancellous Bone/pathology , Densitometry , Female , Femur/drug effects , Femur/pathology , Femur/physiopathology , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/pathology , Lumbar Vertebrae/physiopathology , Organ Size/drug effects , Rats, Sprague-Dawley , Time Factors , Wnt Proteins/genetics , Wnt Proteins/metabolism
2.
Cell Metab ; 11(2): 161-71, 2010 Feb 03.
Article in English | MEDLINE | ID: mdl-20142103

ABSTRACT

Parathyroid hormone (PTH) suppresses Dickkopf 1 (Dkk1) expression in osteoblasts. To determine whether this suppression is essential for PTH-mediated Wnt signaling and bone formation, we examined mice that overexpress Dkk1 in osteoblasts (Dkk1 mice). Dkk1 mice were osteopenic due to abnormal osteoblast and osteoclast activity. When fed a low-calcium diet, and in two other models of hyperparathyroidism, these mice failed to develop the peritrabecular stromal cell response ("osteitis fibrosis") and new bone formation seen in wild-type mice. Despite these effects of Dkk1 overexpression, PTH still activated Wnt signaling in Dkk1 mice and in osteoblastic cells cultured from these mice. In cultured MC3T3E1 preosteoblastic cells, PTH dramatically suppressed Dkk1 expression, induced PKA-mediated phosphorylation of beta-catenin, and significantly enhanced Lef1 expression. Our findings indicate that the full actions of PTH require intact Wnt signaling but that PTH can activate the Wnt pathway despite overexpression of Dkk1.


Subject(s)
Intercellular Signaling Peptides and Proteins/metabolism , Osteogenesis , Parathyroid Hormone/metabolism , Stromal Cells/metabolism , Wnt Proteins/metabolism , Animals , Bone Marrow Cells/metabolism , Cell Line , Cell Proliferation , Cells, Cultured , Gene Expression Regulation , Humans , Intercellular Signaling Peptides and Proteins/genetics , Mice , Mice, Inbred C57BL , Osteoblasts/metabolism , Osteoclasts/metabolism , RNA, Messenger/genetics , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...